Barinthus Biotherapeutics plc

NasdaqGM:BRNS Rapporto sulle azioni

Cap. di mercato: US$36.0m

Barinthus Biotherapeutics Gestione

Gestione criteri di controllo 2/4

Barinthus Biotherapeutics Il CEO è Bill Enright, nominato in Aug2019, e ha un mandato di 5.25 anni. la retribuzione annua totale è $ 1.81M, composta da 33.7% di stipendio e 66.3% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 3.09% delle azioni della società, per un valore di $ 1.11M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.8 anni e 4.8 anni.

Informazioni chiave

Bill Enright

Amministratore delegato

US$1.8m

Compenso totale

Percentuale dello stipendio del CEO33.7%
Mandato del CEO5.3yrs
Proprietà del CEO3.1%
Durata media del management1.8yrs
Durata media del Consiglio di amministrazione4.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Barinthus Biotherapeutics plc (NASDAQ:BRNS) Not Doing Enough For Some Investors As Its Shares Slump 32%

Nov 19
Barinthus Biotherapeutics plc (NASDAQ:BRNS) Not Doing Enough For Some Investors As Its Shares Slump 32%

Is Barinthus Biotherapeutics (NASDAQ:BRNS) In A Good Position To Invest In Growth?

Aug 31
Is Barinthus Biotherapeutics (NASDAQ:BRNS) In A Good Position To Invest In Growth?

Here's Why We're Watching Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn Situation

Apr 05
Here's Why We're Watching Barinthus Biotherapeutics' (NASDAQ:BRNS) Cash Burn Situation

We Think Vaccitech (NASDAQ:VACC) Can Afford To Drive Business Growth

Jul 07
We Think Vaccitech (NASDAQ:VACC) Can Afford To Drive Business Growth

Vaccitech's (NASDAQ:VACC) Earnings Are Of Questionable Quality

Nov 17
Vaccitech's (NASDAQ:VACC) Earnings Are Of Questionable Quality

Vaccitech promotes Gemma Brown to CFO

Sep 20

Analysts Just Made An Incredible Upgrade To Their Vaccitech plc (NASDAQ:VACC) Forecasts

Aug 15
Analysts Just Made An Incredible Upgrade To Their Vaccitech plc (NASDAQ:VACC) Forecasts

Vaccitech plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 13
Vaccitech plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Vaccitech GAAP EPS of $0.41, revenue of $17.06M

Aug 09

Growth Investors: Industry Analysts Just Upgraded Their Vaccitech plc (NASDAQ:VACC) Revenue Forecasts By 51%

May 19
Growth Investors: Industry Analysts Just Upgraded Their Vaccitech plc (NASDAQ:VACC) Revenue Forecasts By 51%

Vaccitech: Aiming For A Cure In Chronic Hepatitis B

Apr 03

Vaccitech: The Next Big Vaccine Trade

Jun 27

Vaccitech EPS misses by $0.69, beats on revenue

Jun 14

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Bill Enright rispetto agli utili di Barinthus Biotherapeutics?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

-US$58m

Jun 30 2024n/an/a

-US$64m

Mar 31 2024n/an/a

-US$71m

Dec 31 2023US$2mUS$610k

-US$73m

Sep 30 2023n/an/a

-US$77m

Jun 30 2023n/an/a

-US$55m

Mar 31 2023n/an/a

-US$15m

Dec 31 2022US$2mUS$569k

US$5m

Sep 30 2022n/an/a

US$11m

Jun 30 2022n/an/a

-US$1m

Mar 31 2022n/an/a

-US$33m

Dec 31 2021US$3mUS$474k

-US$51m

Sep 30 2021n/an/a

-US$46m

Jun 30 2021n/an/a

-US$41m

Mar 31 2021n/an/a

-US$29m

Dec 31 2020US$3mUS$350k

-US$18m

Dec 31 2019US$381kUS$128k

-US$21m

Compensazione vs Mercato: La retribuzione totale di Bill ($USD 1.81M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 649.07K ).

Compensazione vs guadagni: La retribuzione di Bill è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Bill Enright (62 yo)

5.3yrs

Mandato

US$1,811,611

Compensazione

Mr. William J. Enright, also known as Bill, MBA, is an Independent Director of Bullfrog AI Holdings, Inc. from February 14, 2023. He serves as Chief Executive Officer & Director of Barinthus Biotherapeutic...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
William Enright
CEO & Director5.3yrsUS$1.81m3.09%
$ 1.1m
Graham Griffiths
Chief Operating Officerless than a yearUS$731.06k0.26%
$ 93.2k
Nadege Pelletier
Chief Scientific Officer1.8yrsUS$1.71m0%
$ 0
Sarah Gilbert
Co-Founderno dataUS$48.98kNessun dato
Adrian Hill
Co-Founder & Scientific Advisorno dataUS$61.61kNessun dato
Gemma Brown
CFO & Company Secretary2.2yrsNessun datoNessun dato
Elizabeth Eagling-Vose
Head of Clinical Operationsno dataNessun datoNessun dato
Bernie McDonald
Head of IPno dataNessun datoNessun dato
Geoffrey Lynn
Senior Vice President of Synthetic Immunotherapiesno dataNessun datoNessun dato
Leon Hooftman
Chief Medical Officerless than a yearNessun datoNessun dato

1.8yrs

Durata media

45yo

Età media

Gestione esperta: Il team dirigenziale di BRNS non è considerato esperto (durata media 1.8 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
William Enright
CEO & Director5.3yrsUS$1.81m3.09%
$ 1.1m
Karen Dawes
Independent Non-Executive Director3.8yrsUS$81.69k0.0042%
$ 1.5k
Anne Phillips
Independent Non-Executive Director3.8yrsUS$81.06k0.0075%
$ 2.7k
Robin Wright
Independent Chairman of the Board6.3yrsUS$117.13k0.12%
$ 43.2k
Pierre Armand Morgon
Independent Non-Executive Director6.8yrsUS$85.42k0.026%
$ 9.4k
Alex Hammacher
Non-Executive Director4.8yrsUS$71.11k0.0075%
$ 2.7k
Benoit den Eynde
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Mark Tuthill
Member of Scientific Advisory Boardno dataNessun datoNessun dato
Joseph C. Scheeren
Independent Non-Executive Director3.7yrsUS$79.82k0.057%
$ 20.6k

4.8yrs

Durata media

62yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di BRNS sono considerati esperti (durata media dell'incarico 4.8 anni).